MBRX notes on its pipeline page that it is entitled to royalties on an undisclosed HCV target being focused on by MRK and IDIX apparently in the discovery stage based upon the use of MBRX's liver targeting technology. Do you have any idea what they're referring to? Is IDIX actively pursuing additional HCV compounds in the discovery stage employing MBRX technology? I assume that IDX184, IDX375, and IDX136/316 are based entirely on IDIX's own proprietary liver targeting technology.
Market Data 
Markets 
AI
